Masakazu Toi

TL;DR: In this paper, the effects of lapatinib on EGFR/HER2 and downstream signaling targets were analyzed by means of quantitative phosphoproteomics, and the results provided new insights into EGFR and HER2 regulation through region-specific phosphorylation, as well as a global view of the cellular signaling networks associated with the anti-breast cancer action of Lapatinib.

TL;DR: The randomized OlympiA trial as discussed by the authors compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in BRCA1/2pv and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer.

TL;DR: This review focuses on tumor vessel maturity as a potential marker for evaluating treatment response and the application of angiogenesis inhibitors in some types of cancers.

TL;DR: Pre-treatment vessel density by the panendothelial marker anti CD-34 antibody, post-treatment Ki-67 labeling index and VEGFR-2 expression were significantly associated to residual tumor area, and the schedule of neoadjuvant therapy tested was safe and active.

TL;DR: Whether premenopausal women treated with ovarian suppression benefit from aromatase inhibitors is investigated, as distant recurrence invariably results in death from breast cancer several years after the occurrence, whereas locoregional recurrence and new contralateral breast cancer are not usually fatal.